Compare Incyte Corporation (INCY) vs Lockheed Martin Corporation (LMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Lockheed Martin Corporation — how do they compare? Incyte Corporation trades at $112.36 (market cap $22.85B), while Lockheed Martin Corporation trades at $510.58 (market cap $117.22B). The key difference: Lockheed Martin Corporation is far larger — about 5.1× Incyte Corporation's market cap, and Lockheed Martin Corporation pays a 2.72% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Lockheed Martin Corporation for 86 Days on average.
| INCY | LMT | |
|---|---|---|
Market Cap | $22.85B | $117.22B |
Volume | 1,927,029 | 1,101,121 |
Sector | Health | Industrials |
52-Week High | $129.93 | $676.70 |
52-Week Low | $83.80 | $439.19 |
Typical Hold Time | 33 Days | 86 Days |
Enterprise Value | $18.35B | $133.96B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
Lockheed Martin (LMT) trades at $499.22, down 2.14% over the past day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 18.73 and net income margin of 8.16%, though recent quarters saw mixed earnings results. Revenue growth is steady, reaching $75.05B in 2025, and the company maintains a robust dividend history, recently declaring a $3.45 payout. Analyst consensus remains bullish with a $635.33 price target, supported by ongoing defense spending and strategic initiatives like AI integration and Skunk Works innovation.
Outlook for LMT is positive due to solid defense contracts and technological advancements, but risks include fixed-price contract volatility and competitive pressures. The stock offers value with a below-sector P/E and high institutional confidence, though investors should monitor execution on earnings targets and macroeconomic impacts on defense budgets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Lockheed Martin Corporation
Lockheed Martin is the largest defense contractor globally and has dominated the Western market for high-end fighter aircraft since the F-35 program was awarded in 2001. Lockheed's largest segment is aeronautics, which is dominated by the massive F-35 program. Lockheed's remaining segments are rotary and mission systems, which is mainly the Sikorsky helicopter business.
Read more on LMT →
